Novaminsulfon (Metamizole Sodium Monohydrate)

Metamizole sodium inhibits cyclooxygenase enzymes, decreasing the production of prostaglandins that mediate inflammation, pain, and fever. It also has central nervous system activity that contributes to analgesia and antipyresis, providing relief without engaging opioid receptors.

The specific dose of Novaminsulfon is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for metamizole sodium in pregnancy and lactation are limited, and the product is generally classified as contraindicated or to be used only if the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Novaminsulfon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Novaminsulfon differs from traditional NSAIDs by having a distinct pyrazolone structure and a lower risk of gastrointestinal ulceration, but it carries a unique risk of agranulocytosis. Compared with paracetamol, it provides stronger analgesic and antipyretic effects but requires closer hematologic monitoring.

Novaminsulfon should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency throughout its shelf life.

Novaminsulfon is administered orally, typically as tablets or oral solution, and should be taken with water. The exact route (e.g., with or without food) depends on the prescriber’s guidance and the specific formulation supplied.

The most serious adverse reactions include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic responses such as anaphylaxis or Stevens‑Johnson syndrome. Prompt medical attention is required if signs of infection, rash, or breathing difficulties develop.

Novaminsulfon is contraindicated in patients with known hypersensitivity to metamizole or other pyrazolones, those with existing severe blood dyscrasias, and individuals with a history of agranulocytosis. It should also be avoided in patients with severe hepatic or renal impairment unless specifically directed by a physician.